Maruho has filed a patent for a film-forming skin composition that includes two polymers: an ethyl acrylate-methyl methacrylate-trimethylammonium ethyl methacrylate chloride copolymer and an ethyl acrylate-methyl methacrylate copolymer. The composition forms a film on the skin that is highly water-resistant and friction-resistant, but can be easily washed off. GlobalData’s report on Maruho gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Maruho, Nanoparticle drug conjugates was a key innovation area identified from patents. Maruho's grant share as of September 2023 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230277476A1) describes a film-forming skin composition for the treatment of hemangioma, particularly in infants. The composition consists of two polymers: an ethyl acrylate-methyl methacrylate-trimethylammonium ethyl methacrylate chloride copolymer (a1) and an ethyl acrylate-methyl methacrylate copolymer (a2).
Claim 2 states that the composition includes propranolol or a pharmaceutically acceptable salt thereof as a medicinal ingredient. Propranolol is a commonly used medication for the treatment of hemangioma, a benign tumor of blood vessels.
Claim 3 specifies that the composition is specifically designed for the treatment of hemangioma. This suggests that the combination of the two polymers and propranolol may have a synergistic effect in treating this condition.
Claim 4 further emphasizes that the composition is particularly suitable for the treatment of hemangioma in infants. Hemangioma is a common vascular anomaly in infants, and finding effective and safe treatment options is crucial.
Claim 5 provides a weight ratio range of the two polymers, stating that the polymer (a1) to polymer (a2) ratio should be between 8:2 and 2:8. This ratio may have been determined through experimentation to achieve optimal film-forming properties.
Claim 6 states that the composition contains 36% or more of water, excluding propellants in aerosol formulations. The inclusion of water may contribute to the film-forming properties and overall formulation stability.
Claim 7 introduces the addition of a surfactant to the composition. The surfactant is specified to be a nonionic surfactant and/or an amphoteric surfactant. Surfactants are commonly used in skincare formulations to improve spreadability and enhance the stability of emulsions.
Claim 8 further specifies that the surfactant used in the composition is a nonionic surfactant and/or an amphoteric surfactant. This choice of surfactant may have been made to ensure compatibility with the other components of the composition.
Claim 9 mentions the inclusion of one or more plasticizers in the composition. These plasticizers can be selected from a group of compounds that are liquid at ordinary temperature, such as ester compounds and aromatic alcohols, as well as medium-polar solid ester compounds and terpenes. Plasticizers are commonly used in film-forming compositions to improve flexibility and adherence to the skin.
Claim 10 states that the composition is substantially free of lower monohydric alcohols. This exclusion may have been made to avoid potential drying or irritating effects on the skin.
In summary, the filed patent describes a film-forming skin composition for the treatment of hemangioma, particularly in infants. The composition includes specific polymers, propranolol or a pharmaceutically acceptable salt thereof, water, a surfactant, and optional plasticizers. The formulation is designed to be effective, safe, and suitable for use on the skin.
To know more about GlobalData’s detailed insights on Maruho, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
